| Oct 1 |
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Sep 5 |
Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics Looks Ripe for a Turnaround
|
| Sep 5 |
Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround
|
| Sep 3 |
Karyopharm to Participate at Upcoming Investor Conferences
|
| Sep 2 |
Pipeline Moves: Investigator-led oncology cell therapy trial terminated
|
| Aug 9 |
Karyopharm Therapeutics Inc. (KPTI) Q2 2024 Earnings Call Transcript
|
| Aug 9 |
With 58% ownership, Karyopharm Therapeutics Inc. (NASDAQ:KPTI) boasts of strong institutional backing
|
| Aug 7 |
Q2 2024 Karyopharm Therapeutics Inc Earnings Call
|
| Aug 7 |
Karyopharm Therapeutics (KPTI) Q2 2024 Earnings Call Transcript
|
| Aug 6 |
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
|
